title: Opposing effects of a tyrosine-based sorting motif and a PDZ-binding motif regulate human T-lymphotropic virus type 1 envelope trafficking.
abstract: Human T-lymphotropic virus type 1 (HTLV-1) envelope (Env) glycoprotein mediates binding of the virus to its receptor on the surface of target cells and subsequent fusion of virus and cell membranes. To better understand the mechanisms that control HTLV-1 Env trafficking and activity, we have examined two protein-protein interaction motifs in the cytoplasmic domain of Env. One is the sequence YSLI, which matches the consensus YXXPhi motifs that are known to interact with various adaptor protein complexes; the other is the sequence ESSL at the C terminus of Env, which matches the consensus PDZ-binding motif. We show here that mutations that destroy the YXXPhi motif increased Env expression on the cell surface and increased cell-cell fusion activity. In contrast, mutation of the PDZ-binding motif greatly diminished Env expression in cells, which could be restored to wild-type levels either by mutating the YXXPhi motif or by silencing AP2 and AP3, suggesting that interactions with PDZ proteins oppose an Env degradation pathway mediated by AP2 and AP3. Silencing of the PDZ protein hDlg1 did not affect Env expression, suggesting that hDlg1 is not a binding partner for Env. Substitution of the YSLI sequence in HTLV-1 Env with YXXPhi elements from other cell or virus membrane-spanning proteins resulted in alterations in Env accumulation in cells, incorporation into virions, and virion infectivity. Env variants containing YXXPhi motifs that are predicted to have high-affinity interaction with AP2 accumulated to lower steady-state levels. Interestingly, mutations that destroy the YXXPhi motif resulted in viruses that were not infectious by cell-free or cell-associated routes of infection. Unlike YXXPhi, the function of the PDZ-binding motif manifests itself only in the producer cells; AP2 silencing restored the incorporation of PDZ-deficient Env into virus-like particles (VLPs) and the infectivity of these VLPs to wild-type levels.
authors.affiliation: NCI-Frederick, Bldg. 535, Rm. 134, Frederick, MD 21702-1201, USA. ilinskayaa@ncifcrf.gov
authors.forename: Anna
authors.initials: A
authors.lastname: Ilinskaya
authors.forename: Gisela
authors.initials: G
authors.lastname: Heidecker
authors.forename: David
authors.initials: D
authors.lastname: Derse
mesh_terms: D033962:Adaptor Protein Complex 2 / Q000235:genetics / Q000378:metabolism; D033963:Adaptor Protein Complex 3 / Q000235:genetics / Q000378:metabolism; D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D020816:Amino Acid Motifs / Q000235:genetics*; D002459:Cell Fusion; D002460:Cell Line; D000074288:Discs Large Homolog 1 Protein; D015686:Gene Products, env / Q000235:genetics / Q000378:metabolism*; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000378:metabolism; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism; D008969:Molecular Sequence Data; D054731:PDZ Domains / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics / Q000378:metabolism; D014443:Tyrosine / Q000235:genetics* / Q000378:metabolism
chemical_list: D033962:Adaptor Protein Complex 2; D033963:Adaptor Protein Complex 3; D048868:Adaptor Proteins, Signal Transducing; C513314:DLG1 protein, human; D000074288:Discs Large Homolog 1 Protein; D015686:Gene Products, env; D008565:Membrane Proteins; D034741:RNA, Small Interfering; D014443:Tyrosine
references.citation: Immunity. 2005 Jun;22(6):655-6
references.pmid: 15963778
references.citation: PLoS Biol. 2008 Sep 30;6(9):e239
references.pmid: 18828675
references.citation: J Virol. 2008 Jul;82(14):7135-43
references.pmid: 18480461
references.citation: J Virol. 2003 May;77(9):5192-200
references.pmid: 12692221
references.citation: Traffic. 2007 May;8(5):462-70
references.pmid: 17376169
references.citation: Curr Biol. 2001 Jun 5;11(11):896-900
references.pmid: 11516654
references.citation: J Virol. 1997 Jul;71(7):5696-702
references.pmid: 9188652
references.citation: Mol Biol Rep. 2003 Jun;30(2):69-82
references.pmid: 12841577
references.citation: PLoS Biol. 2009 Jul;7(7):e1000163
references.pmid: 19636361
references.citation: Annu Rev Biochem. 2003;72:395-447
references.pmid: 12651740
references.citation: J Cell Sci. 2004 Aug 1;117(Pt 17):3983-93
references.pmid: 15286176
references.citation: Cell Struct Funct. 2003 Oct;28(5):419-29
references.pmid: 14745134
references.citation: J Virol. 1999 Nov;73(11):9659-63
references.pmid: 10516080
references.citation: Virology. 2004 Jun 20;324(1):173-83
references.pmid: 15183064
references.citation: Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3443-7
references.pmid: 1565636
references.citation: J Biol Chem. 1995 Jan 6;270(1):214-7
references.pmid: 7814377
references.citation: Science. 2003 Mar 14;299(5613):1713-6
references.pmid: 12589003
references.citation: J Virol. 1994 Mar;68(3):1773-81
references.pmid: 8107239
references.citation: Proc Natl Acad Sci U S A. 2002 May 14;99(10):6755-60
references.pmid: 11997454
references.citation: Mol Pharmacol. 2005 May;67(5):1388-90
references.pmid: 15713849
references.citation: Virus Genes. 1990 Feb;3(3):235-49
references.pmid: 2189258
references.citation: Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2915-20
references.pmid: 17299050
references.citation: Front Biosci (Landmark Ed). 2009 Jun 01;14:5339-60
references.pmid: 19482617
references.citation: J Immunol. 1986 Nov 1;137(9):2945-51
references.pmid: 2428880
references.citation: Curr Top Microbiol Immunol. 2005;285:219-54
references.pmid: 15609506
references.citation: J Biol Chem. 1995 Mar 3;270(9):4933-42
references.pmid: 7876268
references.citation: Mol Biol Cell. 2005 Sep;16(9):4231-42
references.pmid: 15987739
references.citation: EMBO J. 2004 Jan 14;23(1):54-65
references.pmid: 14685283
references.citation: Nat Rev Neurosci. 2004 Oct;5(10):771-81
references.pmid: 15378037
references.citation: J Virol. 2001 Sep;75(18):8461-8
references.pmid: 11507191
references.citation: Mol Biol Cell. 2007 Jul;18(7):2698-706
references.pmid: 17494869
references.citation: J Infect Dis. 2003 Aug 1;188(3):424-7
references.pmid: 12870124
references.citation: J Virol. 1984 Nov;52(2):492-500
references.pmid: 6333515
references.citation: Virus Genes. 2008 Aug;37(1):9-15
references.pmid: 18461433
references.citation: J Virol. 1999 Feb;73(2):1350-61
references.pmid: 9882340
references.citation: J Virol. 1997 May;71(5):3613-9
references.pmid: 9094634
references.citation: J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S85-91
references.pmid: 8797709
references.citation: Virology. 2000 Oct 25;276(2):455-65
references.pmid: 11040136
references.citation: Adv Drug Deliv Rev. 2003 Nov 14;55(11):1405-19
references.pmid: 14597138
references.citation: PLoS One. 2008 May 28;3(5):e2251
references.pmid: 18509526
references.citation: Science. 1998 Apr 17;280(5362):431-4
references.pmid: 9545220
references.citation: J Virol. 2000 Dec;74(24):11734-43
references.pmid: 11090173
references.citation: Oncogene. 2005 Sep 5;24(39):6016-25
references.pmid: 16155608
references.citation: Sci STKE. 2003 Apr 22;2003(179):RE7
references.pmid: 12709532
references.citation: J Biol Chem. 1998 Oct 2;273(40):25915-21
references.pmid: 9748267
references.citation: Annu Rev Neurosci. 2001;24:1-29
references.pmid: 11283303
references.citation: Nat Rev Mol Cell Biol. 2009 Sep;10(9):583-96
references.pmid: 19696796
references.citation: Curr Top Microbiol Immunol. 1990;157:187-253
references.pmid: 2203609
references.citation: PLoS Pathog. 2010 Feb 26;6(2):e1000788
references.pmid: 20195464
references.citation: J Gen Virol. 2002 Sep;83(Pt 9):2241-2246
references.pmid: 12185279
references.citation: J Biol Chem. 1999 Mar 12;274(11):7278-85
references.pmid: 10066790
references.citation: Cell. 2006 Oct 6;127(1):35-7
references.pmid: 17018271
references.citation: J Biol Chem. 1998 Jun 19;273(25):15773-8
references.pmid: 9624176
references.citation: Cell. 2006 Oct 6;127(1):113-24
references.pmid: 17018281